Vitti Labs Announces FDA Approval of Phase II IND Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Pulmonary Fibrosis Secondary to Novel Corona Virus Infection (COVID-19)

On May 2, 2022, Vitti Labs, an AATB-Accredited tissue bank focused on life science research, development, and manufacturing, announced that the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug Application (IND) to move forward with a Phase II Outpatient Clinical Trial using a combination of umbilical cord mesenchymal stem cells and mesenchymal stem cell exosomes for the treatment of treatment of pulmonary fibrosis secondary to novel corona virus infection (COVID-19). Vitti Labs is the first to bring a Phase II trial for this treatment using these therapeutics.